Skip to content
10-Q

Quarterly Report

Amphastar Pharmaceuticals, Inc. AMPH

0001297184-25-000029

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 1, 2025 47.14M sh
Short Term Investments Q1 2025 · Mar 31, 2025 $54.1M
Short Term Investments Q1 2025 · Dec 31, 2024 $70.04M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $182.78M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $151.61M
Current Liabilities Q1 2025 · Mar 31, 2025 $199.05M
Current Liabilities Q1 2025 · Dec 31, 2024 $173.76M
Total Liabilities Q1 2025 · Mar 31, 2025 $874.99M
Total Liabilities Q1 2025 · Dec 31, 2024 $845.17M
Current Assets Q1 2025 · Mar 31, 2025 $587.96M
Current Assets Q1 2025 · Dec 31, 2024 $534.07M
Total Assets Q1 2025 · Mar 31, 2025 $1.63B
Total Assets Q1 2025 · Dec 31, 2024 $1.58B
Shares Diluted Q1 2025 · Mar 31, 2024 53.01M sh
Capex Q1 2025 · Mar 31, 2024 $8.79M
Operating Cash Flow Q1 2025 · Mar 31, 2024 $55.29M
Eps Diluted Q1 2025 · Mar 31, 2024 $0.81
Eps Basic Q1 2025 · Mar 31, 2024 $0.90
Sga Expense Q1 2025 · Mar 31, 2024 $15.68M
Rd Expense Q1 2025 · Mar 31, 2024 $17.04M
Net Income Q1 2025 · Mar 31, 2024 $43.18M
Operating Income Q1 2025 · Mar 31, 2024 $48.01M
Gross Profit Q1 2025 · Mar 31, 2024 $90.1M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $81.74M
Revenue Q1 2025 · Mar 31, 2024 $171.84M